PolyCore Therapeutics LLC is a drug development company spinout from Drexel University focused on development of products for CNS disorders. The initial product in development, PCT-3010, is a biased signaling D3 agonist, a breakthrough once-a-day oral therapy for Parkinson’s disease that improves motor symptoms without development of drug tolerance or dyskinesia.

The product will be utilized as monotherapy or as an adjunct to L-dopa to prolong the efficacy time of L-dopa and reduce L-dopa induced dyskinesia. This is a multi-billion per year market opportunity in the US. The founders of PolyCore Therapeutics, Sandhya Kortagere Ph.D, Associate Professor Drexel University College of Medicine, and Jim Harris, Life Science Entrepreneur and former Merck Executive, formed the company in December 2014.

PolyCore Therapeutics operates out of the Left bank office of Drexel University at 3180 Chestnut Street, Suite 104 in Philadelphia PA. PolyCore’s strategy is to keep infrastructure small, contracting with experts and providers to develop their technologies and help run the company. Informal advisors provide input and direction as needed. Ultimately, developed technologies will be licensed or sold to strategic pharmaceutical companies.

PolyCore has licensed a robust estate of allowed and in-prosecution patent applications for the lead compound, PCT-3010 under both pharmaceutical composition claims as well as method of use claims. Additional backup compounds are claimed in pharmaceutical composition and composition of matter claims as applicable. All existing patent applications relating to PCT-3010, related backup compounds and methods of use have been licensed from Drexel and Rutgers.